These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17182591)

  • 41. Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment.
    Weigt SS; Wallace WD; Derhovanessian A; Saggar R; Saggar R; Lynch JP; Belperio JA
    Semin Respir Crit Care Med; 2010 Apr; 31(2):189-207. PubMed ID: 20354932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimicrobial peptides in lung transplant recipients with bronchiolitis obliterans syndrome.
    Anderson RL; Hiemstra PS; Ward C; Forrest IA; Murphy D; Proud D; Lordan J; Corris PA; Fisher AJ
    Eur Respir J; 2008 Sep; 32(3):670-7. PubMed ID: 18508823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differentiated transplant derived airway epithelial cell cytokine secretion is not regulated by cyclosporine.
    Floreth T; Stern E; Tu Y; Stern R; Garrity ER; Bhorade SM; White SR
    Respir Res; 2011 Apr; 12(1):44. PubMed ID: 21477368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for bronchiolitis obliterans syndrome.
    Jaramillo A; Naziruddin B; Zhang L; Reznik SI; Smith MA; Aloush AA; Trulock EP; Patterson GA; Mohanakumar T
    Transplantation; 2001 Apr; 71(7):966-76. PubMed ID: 11349733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of class II major histocompatibility complex antigens (HLA-DR) and lymphocyte subset immunotyping in chronic pulmonary transplant rejection.
    Hasegawa S; Ockner DM; Ritter JH; Patterson GA; Trulock EP; Cooper JD; Wick MR
    Arch Pathol Lab Med; 1995 May; 119(5):432-9. PubMed ID: 7748071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Lymphatic Phenotype of Lung Allografts in Patients With Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome.
    Traxler D; Schweiger T; Schwarz S; Schuster MM; Jaksch P; Lang G; Birner P; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Transplantation; 2017 Feb; 101(2):310-315. PubMed ID: 27163544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?
    Verleden SE; Ruttens D; Vandermeulen E; Vaneylen A; Dupont LJ; Van Raemdonck DE; Verleden GM; Vanaudenaerde BM; Vos R
    Transplantation; 2013 May; 95(9):1167-72. PubMed ID: 23425818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients.
    Berastegui C; Gómez-Ollés S; Sánchez-Vidaurre S; Culebras M; Monforte V; López-Meseguer M; Bravo C; Ramon MA; Romero L; Sole J; Cruz MJ; Román A
    Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 28008659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral tolerance induction by type V collagen downregulates lung allograft rejection.
    Yasufuku K; Heidler KM; O'Donnell PW; Smith GN; Cummings OW; Foresman BH; Fujisawa T; Wilkes DS
    Am J Respir Cell Mol Biol; 2001 Jul; 25(1):26-34. PubMed ID: 11472972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioengineered gold nanoparticles targeted to mesenchymal cells from patients with bronchiolitis obliterans syndrome does not rise the inflammatory response and can be safely inhaled by rodents.
    Cova E; Inghilleri S; Pandolfi L; Morosini M; Magni S; Colombo M; Piloni D; Finetti C; Ceccarelli G; Benedetti L; Cusella MG; Agozzino M; Corsi F; Allevi R; Mrakic-Sposta S; Moretti S; De Gregori S; Prosperi D; Meloni F
    Nanotoxicology; 2017 May; 11(4):534-545. PubMed ID: 28415888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation.
    Todd JL; Palmer SM
    Chest; 2011 Aug; 140(2):502-508. PubMed ID: 21813529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bronchiolitis obliterans syndrome is associated with absence of suppression of peripheral blood Th1 proinflammatory cytokines.
    Hodge G; Hodge S; Chambers D; Reynolds PN; Holmes M
    Transplantation; 2009 Jul; 88(2):211-8. PubMed ID: 19623016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.
    Lobo LJ; Aris RM; Schmitz J; Neuringer IP
    J Heart Lung Transplant; 2013 Jan; 32(1):70-7. PubMed ID: 23260706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of heat shock protein 27 in bronchiolitis obliterans syndrome after lung transplantation.
    Wood KL; Nunley DR; Moffatt-Bruce S; Pope-Harman A; Huang Q; Shamo EN; Phillips GS; Baran C; Batra S; Marsh CB; Doseff AI
    J Heart Lung Transplant; 2010 Jul; 29(7):786-91. PubMed ID: 20456980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts.
    Walker N; Badri L; Wettlaufer S; Flint A; Sajjan U; Krebsbach PH; Keshamouni VG; Peters-Golden M; Lama VN
    Am J Pathol; 2011 Jun; 178(6):2461-9. PubMed ID: 21641374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts.
    Tikkanen JM; Kallio EA; Bruggeman CA; Koskinen PK; Lemström KB
    Am J Respir Crit Care Med; 2001 Aug; 164(4):672-9. PubMed ID: 11520736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.
    Manuel O; Kumar D; Moussa G; Chen MH; Pilewski J; McCurry KR; Studer SM; Crespo M; Husain S; Humar A
    Transplantation; 2009 Mar; 87(5):719-25. PubMed ID: 19295317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transplant-related bronchiolitis obliterans (BOS) demonstrates unique cytokine profiles compared to toxicant-induced BOS.
    Svetlecic J; Molteni A; Chen Y; Al-Hamed M; Quinn T; Herndon B
    Exp Mol Pathol; 2005 Dec; 79(3):198-205. PubMed ID: 16226252
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Ciaramelli C; Fumagalli M; Viglio S; Bardoni AM; Piloni D; Meloni F; Iadarola P; Airoldi C
    J Proteome Res; 2017 Apr; 16(4):1669-1682. PubMed ID: 28245130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel charcoal-induced model of obliterative bronchiolitis-like lesions: implications of chronic nonspecific airway inflammation in the development of posttransplantation obliterative bronchiolitis.
    Lee AG; Wagner FM; Chen MF; Serrick C; Giaid A; Shennib H
    J Thorac Cardiovasc Surg; 1998 Apr; 115(4):822-7. PubMed ID: 9576217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.